Skip to main content
SpringerLink
Log in

Atrial fibrillation and stroke: Four treatment controversies

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Atrial fibrillation is an important cause of disabling ischemic stroke, and adjusteddose warfarin is highly effective for prevention and remains the therapy of choice for high-risk patients. Ximelagatran, a novel oral anticoagulant, is clinically equivalent to warfarin for preventing stroke in patients with atrial fibrillation, but concerns about potential hepatic toxicity have precluded US Food and Drug Administration approval. Many patients with low-risk atrial fibrillation do not benefit substantially from anticoagulation, and these patients can be reliably identified using the CHADS2 stroke risk stratification scheme. A target International Normalized Ratio (INR) range of 2 to 3 is usually recommended for anticoagulation of patients with atrial fibrillation, but a lower INR target (2, range 1.6–2.5) may be a reasonable benefit/risk trade-off for primary prevention in those aged older than 75 years. Adding aspirin to adjusted-dose anticoagulation increases bleeding (including central nervous system bleeding), is of uncertain value, and should only be done after careful consideration and with vigorous efforts to control blood pressure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke. The Framingham Study. Stroke 1991, 22:983–988. Best epidemiological evidence defining atrial fibrillation as a stroke risk factor from the study that made the seminal observations in 1978.

    PubMed  CAS  Google Scholar 

  2. Hart RG, Benavente O, McBride R, Pearce LA: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999, 131:492–501. Meta-analysis of all published randomized data results is a good source of trial results. In general, estimates of efficacy are slightly more conservative than those found in other publications and guideline statements.

    PubMed  CAS  Google Scholar 

  3. Go AS, Hylek EM, Chang Y, et al.: Anticoagulation therapy for stroke prevention in atrial fibrillation. How well do randomized trials translate into clinical practice? JAMA 2003, 290:2685–2692. Large outpatient experience and worth a careful read. Observed stroke rates lower than for many clinical trials and hospital-based surveys may reflect healthier outpatients versus incomplete event detection.

    Article  PubMed  CAS  Google Scholar 

  4. Gage BF, van Walraven C, Pearce LA, et al.: Selecting patients with atrial fibrillation for anticoagulation. Stroke risk stratification in patients taking aspirin. Circulation 2004, 110:2287–2292.

    Article  PubMed  CAS  Google Scholar 

  5. Hart RG, Pearce LA Koudstaal PJ: Transient ischemic attacks in patients with atrial fibrillation. Implications for secondary prevention. Stroke 2004, 35:948–951.

    Article  PubMed  Google Scholar 

  6. Sherman DG, Kim SG, Boop BS, et al.: The occurrence and characteristics of stroke events in the AFFIRM study. Arch Intern Med 2005, 165:1185–1191.

    Article  PubMed  Google Scholar 

  7. Marini C, De Santis F, Sacco S, et al.: Contribution of atrial fibrillation to incidence and outcome of ischemic stroke. Results from a population-based study. Stroke 2005, 36:1115–1119.

    Article  PubMed  Google Scholar 

  8. Hart RG, Pearce LA Miller VT, et al.: Cardioembolic vs. noncardioembolic stroke in atrial fibrillation: frequency and effect of antithrombotic agents. Cerebrovasc Dis 2000, 10:39–43.

    Article  PubMed  CAS  Google Scholar 

  9. Olsson SB, Executive Steering Committee on behalf of the SPORTIF III Investigators: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation: randomized controlled trial. Lancet 2003, 362:1691–1698.

    Article  PubMed  CAS  Google Scholar 

  10. SPORTIF Executive Steering Committee for the SPORTIF V Investigators: Ximelagatran vs. warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. JAMA 2005, 293:690–698.

    Article  Google Scholar 

  11. Akins P, Zoble R, Haley JA et al.: Efficacy of ximelagatran for secondary stroke prevention in atrial fibrillation: pooled analysis of the SPORTIF HI and V clinical trial results [abstract]. Stroke 2005, 36:423.

    Google Scholar 

  12. Gomberg-Maitland M, Frison L, Halperin JL: Activecontrol clinical trials to establish equivalence or non-inferiority: methodological and statistical concepts linked to quality. Am Heart J 2003, 146:398–403.

    Article  PubMed  Google Scholar 

  13. AstraZeneca International: AstraZeneca receives action letter from FDA for Exanta (ximelagatran), October 11, 2004 [press release], http://www.astrazeneca.com/ pressrelease/3285.aspx. Accessed March 16, 2005.

  14. Hohnloser SH, Connolly SJ: Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues. / Cardiovasc Electrophysiol 2003, 14(Suppl 9):S60-S63.

    Article  Google Scholar 

  15. Hart RG, Halperin JL, Pearce LA, et al.: Lessons from the Stroke Prevention in Atrial Fibrillation Trials. Ann Intern Med 2003, 138:831–838.

    PubMed  Google Scholar 

  16. Gage BF, Waterman AD, Shannon W, et al.: Validation of clinical classification schemes for predicting stroke: results of the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864–2870.

    Article  PubMed  CAS  Google Scholar 

  17. Oden A Fahlen M, Hart RG: Optimal INR for prevention of stroke and mortality in atrial fibrillation: a critical appraisal. Thromb Res 2005, In press.

  18. The effect of low-dose warfarin on the risk of stroke in nonrheumatic atrial fibrillation. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990,323:1505-1511.

  19. Ezekowitz MD, Bridgers SL, James KE, et al.: Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992, 327:1406–1412.

    Article  PubMed  CAS  Google Scholar 

  20. Hart RG, Tonarelli SB, Pearce LA: Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 2005, 36:1588–1593.

    Article  PubMed  Google Scholar 

  21. Fang MC, Chang Y, Hylek EM, et al.: Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004, 141:745–752.

    PubMed  Google Scholar 

  22. Hylek EM, Go AS, Chang Y, et al.: Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N EnglJ Med 2003, 349:1019–1026.

    Article  CAS  Google Scholar 

  23. Hart RG: Intensity of anticoagulation to prevent stroke in patients with atrial fibrillation. Ann Intern Med 1998, 128:408.

    PubMed  CAS  Google Scholar 

  24. SingerDE, Albers GW, Dalen JE, et al.: Antithrombotic therapy in atrial fibrillation. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:429S-456S. Recent high-quality, evidence-based guideline thoughtfully reviews all major aspects of antithrombotic therapy in atrial fibrillation. An excellent reference source.

    Article  PubMed  CAS  Google Scholar 

  25. Bleeding during antithrombotic therapy in atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Arch Intern Med 1996, 156:409-416.

  26. Johnson CE, Lim WK, Workman BS: People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up. J Am Geriatr Soc 2005, 53:655–659.

    Article  PubMed  Google Scholar 

  27. Fuster V, Ryden LE, Asinger RW, et al.: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. Circulation 2001, 104:2118–2150. Evidence-based guidelines reflecting the views of the international cardiology community. An excellent reference source.

    PubMed  CAS  Google Scholar 

  28. Shireman TI, Howard PA, Kresowik TF, Eilerbeck EF: Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 2004, 35:2362–2367.

    Article  PubMed  CAS  Google Scholar 

  29. Hart RG, Benavente O, Pearce LA: Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis. Cerebrovasc Dis 1999, 9:215–217.

    Article  PubMed  CAS  Google Scholar 

  30. Berwaerts J, Webster J: Analysis of risk factors involved in oral-anticoagulant-related intracranial hemorrhages. Q J Med 2000, 93:513–521.

    CAS  Google Scholar 

  31. Adjusted-dose warfarin versus low-intensity, fixeddose warfarin plus aspirin for high-risk patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Stroke Prevention in Atrial Fibrillation Investigators. Lancet 1996, 348:633-638.

  32. Lechat P, Lardoux H, Mallet A, et al.: Anticoagulant (flunidone)-aspirin combination in patients with high risk atrial fibrillation. A randomized trial (Fluindone, Fibrillation Auriculaire, Aspirin et Contrast Spontane; FEAACS). Cerebrovasc Dis 2001, 12:245–252.

    Article  PubMed  CAS  Google Scholar 

  33. Perez-Gomez F, Alegria E, Berjon J, et al.: Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular atrial fibrillation and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 2004, 44:1557–1566.

    Article  PubMed  CAS  Google Scholar 

  34. Falk RH: Reconsidering combined antiplatelet and anticoagulant therapy in atrial fibrillation. / Am Coll Cardiol 2004, 44:1567–1569.

    Article  CAS  Google Scholar 

  35. Chapman N, Huxley R, Anderson C, et al.: Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history. The PROGRESS trial. Stroke 2004, 35:116–121. Modest blood pressure lowering (by 9 mm Hg systolic) reduced the rate of intracerebral hemorrhage by 50% during antiplatelet therapy in this landmark randomized trial.

    Article  PubMed  CAS  Google Scholar 

  36. Stollberger C, Finsterer J: Primary and secondary stroke prevention in nonrheumatic atrial fibrillation by oral anticoagulation. Eur Neurol 2003, 50:127–135. Good source for practical aspects of anticoagulation of elderly patients with atrial fibrillation.

    Article  PubMed  CAS  Google Scholar 

  37. Schulman S, Beyth RJ: Risk of bleeding with long-term antithrombotic therapy in atrial fibrillation. Eur Heart J Suppl 2005, 7(Suppl C):C34-C40.

    Article  CAS  Google Scholar 

  38. Miller PSJ, Drummond MF, Langkilde LK, et al.: Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation. Eur Heart J Suppl 2005, 7(Suppl C):C41-C54.

    Article  Google Scholar 

  39. Miller PSJ, Andersson FL, Kalra L: Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated? Stroke 2005, 36:360–366.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Texas Health Science Center, 7703 Floyd Curl Drive, MC# 7883, 78229, San Antonio, TX, USA

    Robert G. Hart MD

Authors
  1. Robert G. Hart MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hart, R.G. Atrial fibrillation and stroke: Four treatment controversies. Curr Treat Options Neurol 7, 491–498 (2005). https://doi.org/10.1007/s11940-005-0049-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-005-0049-4

Keywords

Search

Navigation